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BACKGROUND: Follicle-stimulating hormone (FSH) is fundamental for spermatogenesis and is 
empirically used to treat male idiopathic infertility. In a subgroup of men FSH treatment causes a 
significant improvement of the sperm DNA fragmentation (sDF), a candidate predictor of the 
probability to conceive. However, 40% of men do not show any sDF change during FSH treatment. 
Since the FSH receptor (FSHR) polymorphisms (SNP) p.N680S clearly influences ovarian 
response in women and testicular volume in men, this SNP might be useful to predict response to 
FSH.  
AIM: To evaluate whether sDF improvement in response to FSH therapy depends on FSHR 
p.N680S. 
METHODS: A multicenter, longitudinal, prospective, open label, two arms clinical trial is ongoing. 
So far 61 men with idiopathic male infertility carrier of the homozygous FSHR p.N680S N or S 
genotype, FSH<8 IU/L and sperm DF>15%, were enrolled and 42 completed the study protocol. All 
subjects received 150 IU of recombinant FSH (Gonal f®) every other day for 12 weeks and were 
then followed-up for further 12 weeks after FSH withdrawal. sDF was evaluated by TUNEL/PI 
assay coupled to flow cytometry, resolving two different sperm population, namely: PIbrighter and 
PIdimmer. Ultrasound testicular volume and sperm count were assessed at the centers. The 
centers were blind to the FSHR genotype, which was assessed centrally. 
RESULTS: 25 men (59.5%) were carriers of the p.N680S homozygous N and 17 (40.15%) of the 
homozygous S genotype, respectively. Total sDF (PIbrighter+PIdimmer) was significantly lower at 
the end of the study in patients carriers of the p.N680S N allele than patients carriers of p.N680S S 
allele (p=0.017). Only in patients carriers of the p.N680S N allele, total sDF decreased significantly 
from baseline to the end of the study (p=0.021) and this decrease was entirely sustained by the 
sperm population containing vital sperms (i.e. the PIbrighter fraction) (p=0.008). On the contrary, 
the PIdimmer fraction, which includes only non-vital sperms, was significantly higher in patients 
carriers of the p.N680S S allele than in carriers of N allele (p=0.018). Total sDF was also inversely 
related to total sperm number (p=0.020) and progressive sperm motility (p=0.014). 
CONCLUSIONS: The interim analysis of this ongoing study suggests that a significant 
improvement of total sDF is achieved in men carriers of the p.N680S homozygous N allele after 12 
weeks of FSH treatment. This sDF decrease is explained by the decrease of the PIbrighter 
fraction, representing the subgroup containing vital and mobile sperms. If confirmed, this study 
shows that sDF is a good pharmacodynamics parameter of response to FSH treatment in men with 
the homozygous FSHR p.N680S N allele, paving the way to a pharmacogenetic approach to FSH 
treatment of male idiopathic infertility. (EudraCT 2010-020240-35) 
